Vertex Cell and Genetic Therapies
About this Site
In June 2019, Vertex announced the establishment of a new research site in the Boston area where research, development, and clinical manufacturing for cell and genetic therapies will be primarily based. Cell and genetic therapies represent two rapidly emerging therapeutic modalities with the potential to treat—and even cure—several of the diseases Vertex is focused on, including sickle cell disease, Duchenne muscular dystrophy and type 1 diabetes. Further investment in a research site specifically designed to advance these programs will be key to Vertex’s continued and sustained leadership in these exciting approaches. At Vertex Cell and Genetic Therapies (VCGT) our research teams will bring together the best biology, technologies and enhanced manufacturing capabilities to ensure we bring these cutting-edge transformative therapies to patients as quickly as possible.
Read about the VCGT announcement.
Read more about VCGT from our CEO, Dr. Jeff Leiden, on Vertex Voices.
Read recent news from our collaboration with CRISPR Therapeutics on gene editing for sickle cell disease and beta thalassemia.
Building the Cell and Genetic Therapies Toolbox